BRIM-3 最终总生存结果:维莫非尼对比达卡巴嗪治疗 BRAFV600 突变阳性转移性黑色素瘤
BRIM-3 研究将 675 例初治 BRAFV600 突变阳性转移性黑色素瘤患者按 1:1 随机分配至维莫非尼(960 mg 每日两次)或达卡巴嗪(1000 mg/m2 每 3 周)。最终分析时,维莫非尼组的中位 OS 显著长于达卡巴嗪组(交叉删失 13.6 个月 vs 9.7 个月,HR 0.81,P=0.03);约 3 年后 OS 曲线趋同,可能与达卡巴嗪组交叉及后续治疗有关。
要点
- 维莫非尼组中位 OS 为 13.6 个月,达卡巴嗪组为 9.7 个月(交叉删失,HR 0.81,P=0.03)。
- 不删失交叉时,两组中位 OS 为 13.6 个月 vs 10.3 个月(HR 0.81,P=0.01)。
- 1、2、3、4 年 OS 率:维莫非尼组 56%/30%/21%/17%,达卡巴嗪组 46%/24%/19%/16%。
核心结论
- 在延长随访后,维莫非尼在 BRIM-3 中仍与中位 OS 改善相关。
- 约 3 年后 OS 曲线趋同,可能源于达卡巴嗪组交叉至维莫非尼及接受后续抗癌治疗。
研究设计与样本
- 随机、1:1 分配的 BRIM-3 研究,纳入初治 BRAFV600 突变阳性转移性黑色素瘤患者。
- 2010 年 1 月 4 日至 2010 年 12 月 16 日共随机 675 例:维莫非尼组 337 例,达卡巴嗪组 338 例(其中 84 例交叉至维莫非尼)。
- 给药方案:维莫非尼 960 mg 每日两次;达卡巴嗪 1000 mg/m2 每 3 周。
- OS 与 PFS 为共同主要终点,OS 在意向治疗人群中评估,并分别在有、无对交叉患者数据删失的情况下分析。
主要发现
- 交叉删失时,维莫非尼组中位 OS 13.6 个月(95%CI 12.0-15.4)vs 达卡巴嗪组 9.7 个月(95%CI 7.9-12.8),HR 0.81(95%CI 0.67-0.98),P=0.03。
- 不删失交叉时,维莫非尼组中位 OS 13.6 个月(95%CI 12.0-15.4)vs 达卡巴嗪组 10.3 个月(95%CI 9.1-12.8),HR 0.81(95%CI 0.68-0.96),P=0.01。
- Kaplan-Meier 估计 1、2、3、4 年 OS 率分别为维莫非尼组 56%/30%/21%/17%,达卡巴嗪组 46%/24%/19%/16%。
- 达卡巴嗪组 338 例中 173 例(51%)、维莫非尼组 337 例中 175 例(52%)接受后续抗癌治疗,最常见为伊匹木单抗。
- 安全性数据与主要分析一致。
关键数值与推荐
- 维莫非尼 960 mg 每日两次;达卡巴嗪 1000 mg/m2 每 3 周。
- 交叉删失时中位 OS:维莫非尼组 13.6 个月(95%CI 12.0-15.4)vs 达卡巴嗪组 9.7 个月(95%CI 7.9-12.8),HR 0.81(95%CI 0.67-0.98),P=0.03。
- 不删失交叉时中位 OS:维莫非尼组 13.6 个月(95%CI 12.0-15.4)vs 达卡巴嗪组 10.3 个月(95%CI 9.1-12.8),HR 0.81(95%CI 0.68-0.96),P=0.01。
临床怎么用
- 对于初治 BRAFV600 突变阳性转移性黑色素瘤患者,维莫非尼较达卡巴嗪与更长的中位 OS 相关。
- 解读 OS 结果时需考虑达卡巴嗪组交叉至维莫非尼及后续抗癌治疗(最常见为伊匹木单抗)的影响。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with BRAFV600 mutation-positive metastatic melanoma. We present final OS data from BRIM-3. PATIENTS AND METHODS: Patients were randomly assigned in a 1 : 1 ratio to receive vemurafenib (960 mg twice daily) or dacarbazine (1000 mg/m2 every 3 weeks). OS and PFS were co-primary end points. OS was assessed in the intention-to-treat population, with and without censoring of data for dacarbazine patients who crossed over to vemurafenib. RESULTS: Between 4 January 2010 and 16 December 2010, a total of 675 patients were randomized to vemurafenib (n = 337) or dacarbazine (n = 338, of whom 84 crossed over to vemurafenib). At the time of database lock (14 August 2015), median OS, censored at crossover, was significantly longer for vemurafenib than for dacarbazine {13.6 months [95% confidence interval (CI) 12.0-15.4] versus 9.7 months [95% CI 7.9-12.8; hazard ratio (HR) 0.81 [95% CI 0.67-0.98]; P = 0.03}, as was median OS without censoring at crossover [13.6 months (95% CI 12.0-15.4) versus 10.3 months (95% CI 9.1-12.8); HR 0.81 (95% CI 0.68-0.96); P = 0.01]. Kaplan-Meier estimates of OS rates for vemurafenib versus dacarbazine were 56% versus 46%, 30% versus 24%, 21% versus 19% and 17% versus 16% at 1, 2, 3 and 4 years, respectively. Overall, 173 of the 338 patients (51%) in the dacarbazine arm and 175 of the 337 (52%) of those in the vemurafenib arm received subsequent anticancer therapies, most commonly ipilimumab. Safety data were consistent with the primary analysis. CONCLUSIONS: Vemurafenib continues to be associated with improved median OS in the BRIM-3 trial after extended follow-up. OS curves converged after ≈3 years, likely as a result of crossover from dacarbazine to vemurafenib and receipt of subsequent anticancer therapies. CLINICALTRIALS.GOV: NCT01006980.
引用
- Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017. PMID: 28961848. doi:10.1093/annonc/mdx339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。